Lauren P McLaughlin1, Haili Lang2, Elizabeth Williams2, Kaylor E Wright2, Allison Powell2, Conrad R Cruz3, Anamaris M Colberg-Poley4, Cecilia Barese2, Patrick J Hanley1, Catherine M Bollard5, Michael D Keller6. 1. Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center, Washington, DC, USA. 2. Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC, USA. 3. Sheikh Zayed Institute, Children's National Medical Center, Washington, DC, USA. 4. Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA. 5. Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Medical Center, Washington, DC, USA; Division of Allergy and Immunology, Children's National Medical Center, Washington, DC, USA. 6. Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC, USA; Division of Allergy and Immunology, Children's National Medical Center, Washington, DC, USA. Electronic address: mkeller@cnmc.org.
Abstract
BACKGROUND AIMS: Human parainfluenza virus-3 (HPIV) is a common cause of respiratory infection in immunocompromised patients and currently has no effective therapies. Virus-specific T-cell therapy has been successful for the treatment or prevention of viral infections in immunocompromised patients but requires determination of T-cell antigens on targeted viruses. METHODS: HPIV3-specific T cells were expanded from peripheral blood of healthy donors using a rapid generation protocol targeting four HPIV3 proteins. Immunophenotyping was performed by flow cytometry. Viral specificity was determined by interferon (IFN)-γ ELISpot, intracellular cytokine staining and cytokine measurements from culture supernatants by Luminex assay. Cytotoxic activity was tested by 51Cr release and CD107a mobilization assays. Virus-specific T cells targeting six viruses were then produced by rapid protocol, and the phenotype of HPIV3-specific T cells was determined by immunomagnetic sorting for IFN-γ-producing cells. RESULTS: HPIV3-specific T cells were expanded from 13 healthy donors. HPIV3-specific T cells showed a CD4+ predominance (mean CD4:CD8 ratio 2.89) and demonstrated specificity for multiple HPIV3 antigens. The expanded T cells were polyfunctional based on cytokine production but only had a minor cytotoxic component. T cells targeting six viruses in a single product similarly showed HPIV3 specificity, with a predominant effector memory phenotype (CD3+/CD45RA-/CCR7-) in responder cells. DISCUSSION: HPIV3-specific T cells can be produced using a rapid ex vivo protocol from healthy donors and are predominantly CD4+ T cells with Th1 activity. HPIV3 epitopes can also be successfully targeted alongside multiple other viral epitopes in production of six-virus T cells, without loss of HPIV3 specificity. These products may be clinically beneficial to combat HPIV3 infections by adoptive T-cell therapy in immune-compromised patients.
BACKGROUND AIMS: Human parainfluenza virus-3 (HPIV) is a common cause of respiratory infection in immunocompromised patients and currently has no effective therapies. Virus-specific T-cell therapy has been successful for the treatment or prevention of viral infections in immunocompromised patients but requires determination of T-cell antigens on targeted viruses. METHODS:HPIV3-specific T cells were expanded from peripheral blood of healthy donors using a rapid generation protocol targeting four HPIV3 proteins. Immunophenotyping was performed by flow cytometry. Viral specificity was determined by interferon (IFN)-γ ELISpot, intracellular cytokine staining and cytokine measurements from culture supernatants by Luminex assay. Cytotoxic activity was tested by 51Cr release and CD107a mobilization assays. Virus-specific T cells targeting six viruses were then produced by rapid protocol, and the phenotype of HPIV3-specific T cells was determined by immunomagnetic sorting for IFN-γ-producing cells. RESULTS:HPIV3-specific T cells were expanded from 13 healthy donors. HPIV3-specific T cells showed a CD4+ predominance (mean CD4:CD8 ratio 2.89) and demonstrated specificity for multiple HPIV3 antigens. The expanded T cells were polyfunctional based on cytokine production but only had a minor cytotoxic component. T cells targeting six viruses in a single product similarly showed HPIV3 specificity, with a predominant effector memory phenotype (CD3+/CD45RA-/CCR7-) in responder cells. DISCUSSION: HPIV3-specific T cells can be produced using a rapid ex vivo protocol from healthy donors and are predominantly CD4+ T cells with Th1 activity. HPIV3 epitopes can also be successfully targeted alongside multiple other viral epitopes in production of six-virus T cells, without loss of HPIV3 specificity. These products may be clinically beneficial to combat HPIV3 infections by adoptive T-cell therapy in immune-compromised patients.
Authors: Emily Blyth; Leighton Clancy; Renee Simms; Chun K K Ma; Jane Burgess; Shivashni Deo; Karen Byth; Ming-Celine Dubosq; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb Journal: Blood Date: 2013-02-22 Impact factor: 22.113
Authors: Dirk H Busch; Simon P Fräßle; Daniel Sommermeyer; Veit R Buchholz; Stanley R Riddell Journal: Semin Immunol Date: 2016-03-11 Impact factor: 11.130
Authors: Ann M Leen; Anne Christin; Gary D Myers; Hao Liu; Conrad R Cruz; Patrick J Hanley; Alana A Kennedy-Nasser; Kathryn S Leung; Adrian P Gee; Robert A Krance; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard Journal: Blood Date: 2009-08-21 Impact factor: 22.113
Authors: Tobias Feuchtinger; Celine Richard; Stefanie Joachim; Michael H Scheible; Michael Schumm; Klaus Hamprecht; David Martin; Gerhard Jahn; Rupert Handgretinger; Peter Lang Journal: J Immunother Date: 2008 Feb-Mar Impact factor: 4.456
Authors: Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup Journal: Blood Date: 2006-02-07 Impact factor: 22.113
Authors: Chun K K Ma; Emily Blyth; Leighton Clancy; Renee Simms; Jane Burgess; Rebecca Brown; Shivashni Deo; Kenneth P Micklethwaite; David J Gottlieb Journal: Cytotherapy Date: 2015-10 Impact factor: 5.414
Authors: Janet A Englund; Ruth A Karron; Coleen K Cunningham; Philip Larussa; Ann Melvin; Ram Yogev; Ed Handelsman; George K Siberry; Bhavanji Thumar; Elizabeth Schappell; Catherine V Bull; Helen Y Chu; Anne Schaap-Nutt; Ursula Buchholz; Peter L Collins; Alexander C Schmidt Journal: Vaccine Date: 2013-10-05 Impact factor: 3.641
Authors: Allistair A Abraham; Tami D John; Michael D Keller; C Russell N Cruz; Baheyeldin Salem; Lauren Roesch; Hao Liu; Fahmida Hoq; Bambi J Grilley; Adrian P Gee; Hema Dave; David A Jacobsohn; Robert A Krance; Elizabeth J Shpall; Caridad A Martinez; Patrick J Hanley; Catherine M Bollard Journal: Blood Adv Date: 2019-07-23
Authors: Maria Cancio; Rachele Ciccocioppo; Patricia R M Rocco; Bruce L Levine; Vincenzo Bronte; Catherine M Bollard; Daniel Weiss; Jaap Jan Boelens; Patrick J Hanley Journal: Cytotherapy Date: 2020-05-07 Impact factor: 5.414
Authors: Paul Castillo; Kaylor E Wright; Dimitrios P Kontoyiannis; Thomas Walsh; Shabnum Patel; Elizabeth Chorvinsky; Swaroop Bose; Yasmin Hazrat; Bilal Omer; Nathaniel Albert; Ann M Leen; Cliona M Rooney; Catherine M Bollard; Conrad Russell Y Cruz Journal: Mol Ther Methods Clin Dev Date: 2018-03-14 Impact factor: 6.698